Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC: Cabozantinib, Nivolumab, and Ipilimumab in Rare Genitourinary Cancers
NCT03866382Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Feb 2027
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib, nivolumab and ipilimumab in genitourinary cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 5 years. Started May 2019; status: recruiting.
02
Drugs
03
Conditions
genitourinary cancer
Beyond the preview
Go deeper on NCT03866382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866382.